Non-canonical signaling mechanisms of short-chain fatty acid receptors in glucagon-like peptide-1 (GLP-1) releasing enteroendocrine cells

This study reveals that short-chain fatty acids and ketone bodies differentially regulate GLP-1 secretion in enteroendocrine cells by activating FFA2 and FFA3 receptors through distinct, non-canonical intracellular signaling pathways that operate independently of or diverge from traditional G-protein mechanisms.

The Gist

The Big Picture: The Gut's "Control Center"

Imagine your gut (specifically the colon) is a busy factory. Inside this factory, there are tiny workers called Enteroendocrine Cells (EECs). Their main job is to send out "emergency messages" in the form of a hormone called GLP-1.

Why do we need GLP-1? Think of GLP-1 as a super-messenger that tells your pancreas, "Hey, we just ate! Make more insulin!" and tells your stomach, "Slow down the food delivery, we're full!" This is crucial for managing blood sugar and weight.

For a long time, scientists knew these workers reacted to food. But they didn't know exactly how they sensed the specific chemicals left over after digestion. This paper investigates two specific "ears" (receptors) on these workers: FFA2 and FFA3.

These ears listen to two types of signals:

1. Short-Chain Fatty Acids (SCFAs): These are like "leftover snacks" produced by the good bacteria in your gut when they ferment fiber.
2. Ketone Bodies: These are "emergency fuel" your body makes when you are fasting, on a keto diet, or exercising hard.

The researchers wanted to know: Do these ears tell the factory to speed up (release more GLP-1) or slow down (release less)? And what is the internal wiring that makes that happen?

---

The Discovery: A Tale of Two Ears

The team found that these two ears, while looking similar, act like opposite switches with very strange wiring.

1. The "Brake" Ear (FFA2)

• The Signal: When the "leftover snacks" (SCFAs) or "emergency fuel" (Acetoacetate) hit this ear, it acts like a brake.
• The Result: It tells the factory to stop sending out GLP-1 messages.
• The Weird Wiring: Usually, when a receptor like this gets a signal, it follows a standard rulebook (using a protein called Gᵢ to lower cAMP, a chemical messenger). But this ear is a rebel!
  • It does lower the GLP-1 message, but it does it through a secret, non-standard pathway.
  • It doesn't use the usual "off-switch" proteins. It's like a car that stops not by pressing the brake pedal, but by somehow jamming the engine in a way the manual didn't predict.
  • Analogy: Imagine a security guard (FFA2) who sees a delivery truck (SCFA) and decides to lock the gates. But instead of using the standard key, he pulls a fire alarm that confuses the whole system, yet the gates still lock.

2. The "Gas Pedal" Ear (FFA3)

• The Signal: When a different type of "leftover snack" (Propionate) or a specific type of "emergency fuel" (Beta-hydroxybutyrate) hits this ear, it acts like a gas pedal.
• The Result: It tells the factory to speed up and release more GLP-1.
• The Weird Wiring: This ear also breaks the rules.
  • Standard theory says this ear should lower cAMP (the "go" signal). But here, it actually increases GLP-1 release by using a different internal messenger: Calcium.
  • It's like a factory manager who usually shuts down production when a specific signal comes in, but this time, they decide to open a new assembly line using a different power source (Calcium) instead of the usual electricity (cAMP).
  • Analogy: This is like a traffic light that turns green not by changing the color, but by suddenly making all the cars drive faster on their own.

---

The "Leftover Snacks" vs. "Emergency Fuel"

The researchers also tested specific chemicals to see which ear they tickled:

• Propionate (a common SCFA): It mostly hit the "Brake" ear (FFA2), slowing things down.
• Butyrate (another SCFA): It was a bit of a mixed bag, sometimes speeding things up, sometimes doing nothing.
• Acetoacetate (a Ketone Body): It hit the "Brake" ear, slowing down GLP-1. This makes sense: if you are fasting and burning fat, you don't need to tell your body to store more energy (insulin).
• Beta-hydroxybutyrate (BHB - the main Ketone): Surprisingly, this hit the "Gas Pedal" ear (FFA3) and sped up GLP-1 release!
  • Why is this cool? It suggests that even when you are fasting (low carbs), your body can still use these ketone signals to keep your gut hormones working, perhaps to prepare for when you do eat again.

Why Does This Matter?

Think of your body as a smart thermostat.

• Old View: We thought the thermostat only reacted to the temperature (food) in a simple way.
• New View: This paper shows the thermostat has two different sensors that react to different types of "weather" (fiber leftovers vs. fasting fuel) in complex, non-standard ways.

The Takeaway:
Your gut bacteria and your own metabolism are having a constant, high-tech conversation using these two receptors.

• FFA2 is the "Slow Down" button, often used when there's too much fiber fermentation or specific ketones.
• FFA3 is the "Speed Up" button, used to keep the system responsive even when you aren't eating much.

Because these receptors use "secret wiring" (non-canonical pathways) that scientists didn't expect, it opens up new doors for making better medicines. Instead of just trying to force the system one way, doctors might be able to design drugs that "tweak" these specific secret pathways to help people with diabetes or obesity manage their blood sugar more naturally.

In short: Your gut has a sophisticated, dual-mode radio system that listens to your diet and your bacteria, using secret codes to decide whether to tell your body to store energy or burn it. And we just figured out a few of those codes.

Technical Summary

1. Problem Statement

Enteroendocrine cells (EECs) in the distal gut release Glucagon-like peptide-1 (GLP-1), a hormone critical for glucose homeostasis and satiety. While it is established that Short-Chain Fatty Acids (SCFAs) produced by gut microbiota and Ketone Bodies (KBs) produced by the host modulate GLP-1 secretion via Free Fatty Acid Receptors 2 and 3 (FFA2/GPR43 and FFA3/GPR41), the precise intracellular signaling pathways remain poorly understood.

Previous models, largely based on overexpression systems, suggested canonical signaling: FFA2 couples to $G_{q}$ (increasing $Ca^{2+}$) and $G_{i}$ (decreasing cAMP), while FFA3 couples exclusively to $G_{i}$ (decreasing cAMP). However, these models fail to explain the complex, often opposing, effects of specific nutrients on GLP-1 release in native tissues. This study aims to define the specific signaling mechanisms of FFA2 and FFA3 in endogenous GLP-1-releasing EECs and determine how metabolic states (SCFAs vs. Ketone Bodies) differentially tune GLP-1 secretion.

2. Methodology

The researchers employed a combination of primary cell cultures and a well-characterized cell line to investigate signaling in a physiologically relevant context:

• Models:
  • Primary Mouse Colonic Cultures: Isolated crypts from C57BL/6 mice, enriched for GLP-1-releasing cells.
  • GLUTag Cell Line: A murine L-cell line used as a model for colonic EECs.
• Expression Analysis: Bulk RNA sequencing of FACS-sorted, Venus-tagged GLP-1-releasing cells confirmed the expression of Ffar2 and Ffar3 in both primary cells and GLUTag cells.
• Functional Assays:
  • GLP-1 Secretion: Measured via Sandwich ELISA in response to SCFAs (Acetate, Propionate, Butyrate) and Ketone Bodies (Acetoacetate/AcAc, $\beta$-Hydroxybutyrate/BHB).
  • cAMP Dynamics: Live-cell imaging using the GloSensor-22F cAMP biosensor in GLUTag cells.
  • Intracellular Calcium ($Ca^{2+}$): Ratiometric imaging using Fura-2 AM.
• Pharmacological Tools:
  • Selective Ligands: 4-CMTB and AZ1729 (FFA2 agonists); AR420626 (FFA3 agonist).
  • Signaling Inhibitors/Modulators:
    • Pertussis Toxin (PTX): Uncouples $G_{i/o}$.
    • YM-254890: Blocks $G_{q}$.
    • OZITX: A broad uncoupler of $G_{i/o/\alpha}$.
  • Stimuli: Forskolin (adenylyl cyclase activator) used as a mild stimulus to potentiate secretion and measure cAMP dynamics.

3. Key Results

A. Differential Effects of SCFAs on GLP-1 Secretion

• A physiological mix of SCFAs stimulated GLP-1 secretion in both primary cultures and GLUTag cells.
• Individual SCFAs:
  • Acetate (C2): No significant effect.
  • Propionate (C3): Significantly inhibited GLP-1 release in a dose-dependent manner.
  • Butyrate (C4): Induced a biphasic response (stimulation at low concentrations, no effect at high).
• Conclusion: The net stimulatory effect of SCFA mixtures is likely driven by the integration of opposing signals from different receptors.

B. FFA2 Signaling is Non-Canonical and Ligand-Biased

Activation of FFA2 resulted in the inhibition of GLP-1 secretion, contradicting some previous reports of FFA2 stimulation. The mechanism depends heavily on the ligand:

• 4-CMTB (Orthosteric Agonist):
  • Inhibited GLP-1 release.
  • Paradoxically increased cAMP levels (especially during forskolin stimulation).
  • This increase was PTX-sensitive (implying $G_{i}$ involvement) but did not involve $G_{q}$ (unaffected by YM-254890) and did not trigger $Ca^{2+}$ mobilization.
  • Interpretation: 4-CMTB activates a non-canonical pathway where FFA2 inhibition of secretion is coupled to an unexpected rise in cAMP, independent of classical $G_{q}$ signaling.
• AZ1729 (Allosteric Agonist, $G_{i}$-biased):
  • Inhibited GLP-1 release and decreased cAMP production.
  • Crucially, this inhibition was PTX-insensitive and unaffected by OZITX.
  • Interpretation: AZ1729 stabilizes a distinct FFA2 conformation that inhibits secretion via a novel, non-$G_{i}$ protein family coupling mechanism.

C. FFA3 Signaling is Stimulatory and $Ca^{2+}$-Dependent

• AR420626 (Selective FFA3 Agonist):
  • Stimulated GLP-1 secretion.
  • Did not alter cAMP levels (neither increasing nor decreasing).
  • Triggered a modest, concentration-dependent increase in intracellular $Ca^{2+}$.
  • The secretion was PTX-sensitive, suggesting $G_{i}$ involvement, but the pathway is distinct from canonical cAMP suppression.
  • Interpretation: FFA3 activation likely utilizes a $G_{i}$-mediated pathway where $\beta\gamma$ subunits activate Phospholipase C (PLC), leading to IP3-mediated $Ca^{2+}$ release, which drives exocytosis independent of cAMP changes.

D. Ketone Bodies Modulate Receptors Differentially

• Acetoacetate (AcAc):
  • Inhibited GLP-1 release.
  • Reduced peak cAMP (consistent with FFA2/$G_{i}$ coupling).
  • Conclusion: AcAc acts primarily as an FFA2 agonist.
• $\beta$-Hydroxybutyrate (BHB):
  • Stimulated GLP-1 release at physiological concentrations.
  • Did not alter cAMP or $Ca^{2+}$ levels.
  • Conclusion: BHB likely acts via FFA3 but utilizes a unique, non-canonical pathway distinct from the synthetic agonist AR420626, suggesting endogenous and synthetic ligands stabilize different receptor conformations.

4. Key Contributions

1. Discovery of Ligand Bias in Native Cells: The study demonstrates that FFA2 and FFA3 signaling in native EECs is highly "ligand-biased." Different agonists (e.g., 4-CMTB vs. AZ1729 for FFA2) stabilize distinct receptor conformations leading to opposite downstream effects (cAMP increase vs. decrease) and different secretion outcomes.
2. Non-Canonical Pathways: It challenges the canonical view that FFA2 is purely $G_{q}$/$G_{i}$ coupled and FFA3 is purely $G_{i}$ coupled. The data reveals:
   • FFA2 can increase cAMP without $G_{q}$ and inhibit secretion without $G_{i}$ (via AZ1729).
   • FFA3 can stimulate secretion via $Ca^{2+}$ without altering cAMP.
3. Metabolic Integration: The paper elucidates how the gut integrates different metabolic states:
   • High Carbohydrate/Post-Prandial: SCFAs (specifically butyrate/propionate mix) generally stimulate GLP-1.
   • Fasting/Ketosis: Ketone bodies (AcAc vs. BHB) differentially tune GLP-1, with BHB acting as a stimulator, potentially maintaining GLP-1 levels during low-carb states.

5. Significance

• Therapeutic Implications: Understanding these non-canonical pathways opens new avenues for treating Type 2 Diabetes and obesity. Instead of simply trying to activate FFA2 or FFA3 generally, future drugs could be designed as biased agonists to specifically target the signaling branch that promotes GLP-1 release (e.g., mimicking the BHB/AR420626 effect on FFA3) while avoiding inhibitory pathways.
• Physiological Insight: The findings explain the variability in previous literature (where overexpression systems showed different results) by highlighting that signaling is cell-type and conformation-specific.
• Dietary Context: The study provides a molecular basis for how dietary interventions (high fiber vs. ketogenic diets) differentially impact gut hormone secretion and metabolic health.

In summary, Masse et al. reveal that the "SCFA receptors" in the gut are not simple on/off switches but sophisticated, ligand-specific integrators that use diverse, non-canonical signaling mechanisms to fine-tune GLP-1 secretion based on the body's metabolic state.